Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Antonio Giulio PigaFilomena LongoMaria Rita GamberiniErsi VoskaridouPaolo RicchiVincenzo CarusoAntonello PietrangeloXiaosha ZhangJeevan K ShettyKenneth M AttieImmacolata TartaglionePublished in: Therapeutic advances in hematology (2022)
The results of this study show that in patients with either transfusion-dependent or nontransfusion-dependent β-thalassemia, luspatercept provides lasting reduction in anemia with mostly mild and predictable side effects.